

IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the claims:

Claims 1-35 (cancelled).

Claim 36 (new): A compound which is (2*S*)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable ester thereof.

Claim 37 (new): The compound according to claim 36 wherein said compound is (2*S*)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol.

Claim 38 (new): The compound according to claim 36 wherein the compound is a pharmaceutically acceptable salt of (2*S*)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol.

Claim 39 (new): A pharmaceutical composition which comprises (2*S*)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable ester thereof, in association with a pharmaceutically acceptable diluent or carrier.

Claim 40 (new): The pharmaceutical composition according to claim 39, wherein said composition comprises (2*S*)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol, in association with a pharmaceutically acceptable diluent or carrier.

Claim 41 (**new**): The pharmaceutical composition according to claim 39, wherein composition comprises a pharmaceutically acceptable salt of (2*S*)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol, in association with a pharmaceutically acceptable diluent or carrier.

Claim 42 (**new**): A method for treating a cancer in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of (2*S*)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable ester thereof.

Claim 43 (**new**): The method according to claim 42, wherein said treatment comprises administering to said animal an effective amount of (2*S*)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol.

Claim 44 (**new**): The method according to claim 42, wherein said treatment comprises administering to said animal an effective amount of a pharmaceutically acceptable salt of (2*S*)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol.

Claim 45 (**new**): The method according to claim 42 or 43 wherein said cancer is lung cancer.

Claim 46 (**new**): The method according to claim 42 or 43 wherein said cancer is non-small cell lung cancer.

Claim 47 (**new**): The method according to claim 42 or 43 wherein said cancer is breast cancer.

Claim 48 (new): The method according to claim 42 or 43 wherein said cancer is head and neck cancer.

Claim 49 (new): The method according to claim 42 or 43 wherein said cancer is gastric cancer.

Claim 50 (new): The method according to claim 42 or 43 wherein said cancer is colorectal cancer.

Claim 51 (new): The method according to claim 42 or 43 wherein said cancer is ovarian cancer.

Claim 52 (new): The method according to claim 42 or 43 further comprising the simultaneous, sequential or separate administration to said animal of an effective amount of an additional anti-tumour agent.

Claim 53 (new): A method for treating psoriasis in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of (2S)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable ester thereof.